Dr. Jeffrey Infante on the Positive Results of Using Avelumab in Patients With Ovarian Cancer
Jeffrey R. Infante, MD director of Drug Development, Sarah Cannon Research Institute, talks about the anti-PD-L1 antibody avelumab in patients with previously treated, recurrent or refractory ovarian cancer.
Jeffrey R. Infante, MD director of Drug Development, Sarah Cannon Research Institute, talks about the anti-PD-L1 antibody avelumab in patients with previously treated, recurrent or refractory ovarian cancer.
Infante says avelumab produced positive results in patients during an ovarian cancer study that took place over the course of two months. He says that in some atypical cases during the study, the tumor would appear to progress and then would respond to the treatment.
Infante said that about one-third of the patients in the study were able to stay on the medication for six months and continued to see benefits.
